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a B S t r a c t
BackgrOund: Oxidant/antioxidant imbalance has been reported in various respira-
tory diseases including pneumonia and asthma. However, the role of blood antioxi-
dants has not been fully analyzed.
OBjectiveS: The aim of the present study was to measure and compare serum total 
antioxidant status (TAS) in patients with community-acquired pneumonia (CAP) or 
asthma exacerbation during hospitalization.
MethOdS: Forty-five patients (41 men – 4 women, with a mean age of 4922 years) 
admitted to our hospital with community-acquired pneumonia and 30 patients with 
severe asthma exacerbation (22 men – 8 women, with a mean age of 41.320.7 years), 
as well as 18 normal subjects (40.210 years of age) were included in the study. On 
admission and on the seventh day, serum TAS was measured using a colorimetric 
method at 600 nm.
reSultS: In both groups TAS on admission was decreased compared with normal 
subjects (0.83±0.13 vs. 1.19±0.09 mmol/L, p<0.001 and 0.98±0.08 vs. 1.19±0.09 
mmol/L, p<0.001 respectively). In patients with CAP, but not in asthmatics, TAS 
on discharge was still decreased compared with normals (1.00 ±0.18 vs. 1.19±0.09 
mmol/L, p<0.001). Change of TAS between the first and seventh day was not dif-
ferent between the two groups of patients. Comparison between TAS on admission 
and TAS on discharge revealed statistically significant difference in both groups of 
patients (asthma: 0.98±0.08 vs. 1.13±0.18 mmol/L, p<0.001, pneumonia: 0.83±0.13 
vs. 1.00±0.18 mmol/L, p<0.001). Comparison of TAS on admission and TAS on dis-
charge between the two groups of patients showed that both measurements were sig-
nificantly decreased in patients with pneumonia compared with asthmatics (0.83±0.13 
vs. 0.98±0.08 mmol/L, p<0.001 and 1.00±0.18 vs. 1.13±0.18 mmol/L, p=0.003 re-
spectively). Decreased TAS on admission was found in smokers with pneumonia 
compared with smokers/asthmatics but on discharge this difference was obscured. 
Non-smokers with pneumonia had decreased TAS both on admission and discharge 
compared with non-smokers /asthmatics.
cOncluSiOnS: Serum TAS is decreased in patients with CAP or asthma exacerbation 
suggesting the presence of oxidative stress. Although TAS change during the course 
of the disease is similar, this decrease is more profound in CAP patients on admission 
as well as on discharge.
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i n t r O d u c t i O n
Involvement of oxygen free radicals has been associated with 
a number of pulmonary diseases such as the adult respiratory 
distress syndrome, bronchopneumonic dysplasia, emphysema, 
pneumoconiosis, hyperoxia, bleomycin toxicity, cystic fibrosis, 
bronchial asthma, pneumonia, etc. The source of oxidants varies 
considerably for each specific case.1,2 Oxygen free radicals are 
inactivated by antioxidant mechanisms which include enzymes 
such as superoxide dismutase, catalase, glutathione peroxidase 
and others such as albumin, uric acid, lactofferin, β-carotene, 
vitamins C and E, etc. 3,4
Increased generation of reactive oxygen species in vivo 
can lead to the depletion of one or more antioxidants and 
loss of individual antioxidants can be measured as an index 
of oxidative stress.5 Over the recent years, several attempts 
have been made to assess the total antioxidant activity of body 
fluids rather than specifically identifying what has happened to 
each component of the complex antioxidant defence system.6,7 
There is evidence that interaction between inflammation and 
oxidative stress or antioxidants exists independently of the 
origin of inflammation.8,9 Pneumonia and asthma are both 
inflammatory diseases although totally different with regards 
to the nature of the underlying inflammation; pneumonia is 
characterized by acute inflammation associated with infection 
as opposed to asthma which is considered to be a chronic non 
infectious inflammatory disease.
We have previously shown that serum total antioxidant status 
(TAS) was decreased in patients with severe exacerbation of 
asthma or community acquired pneumonia and correlated with 
the severity of the disease.10,11 The aim of the present study was 
to compare TAS between patients with community-acquired 
pneumonia (CAP) or severe asthma exacerbation during 
hospitalization in an attempt to investigate the response of 
the antioxidant mechanisms of two different inflammatory 
diseases to increased oxidative burden.
P a t i e n t S  a n d  M e t h O d S
Forty-five patients (41 men – 4 women, with a mean age 
of 49.022.1 years) admitted to our hospital for community-
acquired pneumonia and 30 patients with severe asthma ex-
acerbation (22 men – 8 women, with a mean age of 41.320.7 
years) were studied. Eighteen normal subjects (40.210.0 years 
of age) were also included in the study. Patients’ characteristics 
are summarized in Table 1.
Pneumonia was defined as an acute infection of lung 
parenchyma presenting radiologically as a new consolidation 
on chest X-ray accompanied by fever, cough with or without 
purulent or mucopurulent sputum, with or without increased 
white blood cell count (WBC). Admission criteria were based 
upon the CURB index (presence of acute confusion, urea 
nitrogen >7 mmol/l, respiratory rate >30/min, blood pressure 
<90/60 mmHg) and patients with a CURB ≥ 2 were admitted 
to the hospital.12 Sputum Gram stain, sputum culture, blood 
and/or pleural fluid culture were performed for the detection 
of the etiological agent. During the study, all patients received 
antibiotics (amoxycillin+clavulanic acid, a macrolide, second 
or third generation cephalosporin with or without an amino-
glycoside in immunocompromised patients) separately or in 
combination.13 Twenty-nine pneumonia patients were current 
smokers and 16 had pneumonia predisposing factors (heart 
failure, n=10; chronic obstructive pulmonary disease, n=4; 
immunosuppression, n=2).
Diagnosis of asthma was based on symptoms and revers-
ibility of airflow limitation by bronchodilators according to 
GINA guidelines.14 None of the asthmatic patients had a 
history of atopy defined as giving a positive wheal and flare 
response to skin prick testing with several common allergens 
and ten of them were current smokers. All patients were on 
inhaled corticosteroid administration prior to the study. The 
inclusion criteria were based upon low forced expiratory volume 
in one second (FEV1) (<60% predicted) or severe hypoxemia 
(PaO2 <60 mmHg (8 kPa)) or presence of at least one severity 
criterion such as need to be seated, difficulty to speak, use 
of accessory respiratory muscles, respiratory rate >30/min, 
pulse rate >120/min, pulsus paradoxus and also lack of clini-
cal improvement despite intensive medical treatment at the 
emergency department. The cause of the exacerbation of their 
disease was upper or lower respiratory tract infection based 
upon clinical criteria. All patients were treated with nebulised 
bronchodilators (beta2-agonists and ipratropium bromide) as 
well as oral or parenteral steroids, at the same dose, and/or 
taBle 1. Patients’ Characteristics
Pneumonia asthma
Number 45 30
Age (years) 49±22.1 41.3±20.7
PaO2* (mmHg) 72.90±14.27 62.90±10.74
PaO2 ** (mmHg) 79.90±14.80 85.20±10.57
WBC* 13576±5972 8956±2650
WBC** 8764±1353 7485±1753
FEV1*(L/sec) - 1.47±0.71
FEV1**(L/sec) - 2.6±1.12
Smokers (pack years) 29 (18±12.3) 10 (15±17.5)
FEV1= forced expiratory volume at one second; PaO2= partial oxygen 
pressure; WBC= white blood cell count
*on admission; **on discharge
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antibiotics occasionally. The discharge criteria were based 
upon the combination of improved PaO2 (>70 mmHg (9,3kPa)), 
normal respiratory rate and pulse rate, clinical improvement 
and/or improvement of FEV1 (>60%).
In both groups of patients none was receiving oral steroids 
for at least one month prior to the study entry or any kind 
of medication with known antioxidant properties, such as 
trimetazidine, non-steroidal anti-inflammatory drugs such as 
acetylsalicylic acid, nimesulide, etc. Supplemental oxygen was 
given in concentrations no more than 40% to avoid increased 
production of oxidants due to hyperoxia. Patients with severe 
hypoxemia demanding a higher than 40% oxygen concentra-
tion were excluded from the study. On admission and on the 
7th day, blood samples were drawn for complete blood count 
and serum chemistries. Arterial blood was drawn for the 
measurement of partial oxygen pressure (PaO2) on room air. 
The study received the approval of the institutional commit-
tee on human experimentation and all subjects gave written 
informed consent.
c O l l e c t i O n  O f  B l O O d  S a M P l e S  a n d  t a S 
M e a S u r e M e n t
On admission and on the 7th day, 5 ml of venous blood 
sample was centrifuged in 3000 rpm for 10 minutes. Samples 
were collected before supplemental oxygen was administered. 
Serum was removed and stored at –700 C. A kit from Randox 
Ltd (Crumlin, Co Antrim, UK) was used for the measurement, 
based on a colorimetric method suitable for serum samples.15 
In this method, incubation of 2,2΄-azinobis-3-ethylbenothia-
zoline 6-sulphonate (ABTS®) with a peroxide (metmyoglobin) 
results in production of the radical cation ABTS+®. This 
species is blue-green in color, and can be detected at 600 
nm. Antioxidants in the added sample cause inhibition of 
this color production to a degree that is proportional to their 
concentration. A Dimension DU PONT-DADE analyzer was 
used for the measurement and the reagent was calibrated with 
the standards contained in the kit.
S t a t i S t i c a l  a n a lY S i S
Results are expressed as mean ± SD. Paired t-test was 
used for the comparison in measurements of antioxidants 
between the first and seventh day. One way ANOVA was used 
to compare TAS on the first and seventh day between normal 
subjects, pneumonia and asthmatic patients. The Bonferonni 
post hoc test was used to establish differences among groups. 
Unpaired t-test was used to compare TAS values between 
smokers and non smokers in pneumonia and asthmatic patients. 
The Statistical Program for Social Science (SPSS version 17, 
Chicago, IL) was used for the analysis.
r e S u l t S
Pa t i e n t S
The etiological agent was identified in 18 patients (40%) 
based mainly on positive blood cultures or pleural fluid cultures. 
The most common bacteria were Streptococcus pneumoniae 
(10 cases) and Gram (-) (Haemophilus influenzae, Branhamella 
catarallis, Klebsiella and only one case of Acinetobacter in immu-
nocompromised patient). None from the two groups of patients 
studied had to be admitted to the intensive care unit.
t O t a l  a n t i O x i d a n t  S t a t u S  ( t a S )
In both groups (patients with pneumonia and asthmatics), 
TAS on admission was decreased compared with normal sub-
jects (0.83±0.13 vs. 1.19±0.09 mmol/L, p<0.001 and 0.98±0.08 
vs. 1.19±0.09 mmol/L, p<0.001 respectively) (Figure 1). In 
asthmatic patients, TAS on discharge was not statistically dif-
ferent compared with normal subjects (1.13±0.18 vs. 1.19±0.09 
mmol/L, NS). However, in patients with pneumonia, TAS on 
discharge was still decreased compared with normals and this 
was statistically significant (1.00 ±0.18 vs. 1.19±0.09 mmol/L, 
p<0.001) (Figure 1).
Change of TAS between the first and seventh day was 
not significantly different between the two groups of patients 
(0.18±0.20 vs. 0.15±0.14, NS). Comparison between TAS on 
admission and TAS on discharge revealed statistically signifi-
cant difference in both groups of patients (asthma: 0.98±0.08 
vs. 1.13±0.18 mmol/L, p<0.001, pneumonia: 0.83±0.13 vs. 
1.00±0.18 mmol/L, p<0.001) (Figure 2).
Comparison of TAS on admission and TAS on discharge 
between the two groups of patients showed that both measure-
ments were significantly decreased in patients with pneumonia 
compared with asthmatics (0.83±0.13 vs. 0.98±0.08 mmol/L, 
p<0.001 and 1.00±0.18 vs. 1.13±0.18 mmol/L, p=0.003 re-
spectively) (Figure 1).
figure 1. TAS differences among three groups of subjects.
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figure 2. TAS differences on admission and discharge.
When the patients were evaluated according to smoking 
habit, no statistically significant differences were observed on 
admission between smokers and non smokers, both in asthma 
and pneumonia patients. Decreased TAS on admission was 
found in smokers with pneumonia compared with smok-
ers/asthmatics (0.81±0.13 vs. 0.97±0.07 mmol/L, p<0,001). 
However, on discharge this difference was obscured (0.99±0.17 
vs. 1.09±0.12 mmol/L, NS). On the other hand, non-smokers 
with pneumonia had decreased TAS both on admission and 
discharge compared with non-smokers /asthmatics (0.87±0.13 
vs. 0.99±0.10 mmol/L, p=0.01 and 1.01±0.20 vs. 1.18±0.22 
mmol/L, p=0.04 respectively) (Figure 3).
d i S c u S S i O n
The present study demonstrated a significant decrease of 
figure 3. TAS differences between smokers and non smok-
ers.
serum TAS in patients with severe exacerbation of asthma or 
community acquired pneumonia, compared to healthy subjects, 
indicating the presence of oxidant/antioxidant imbalance, 
probably due to increased oxidative load. This imbalance 
has been recently supported by further studies regarding 
both pneumonia and acute exacerbations of asthma. For 
example, increased oxidative stress while decreased enzymic 
and non-enzymic antioxidant activities were demonstrated in 
children with acute pneumonia.16 Increased serum levels of 
reactive oxygen metabolites were found in patients with acute 
exacerbation of asthma17,18 and they decreased after treatment 
with systemic steroids and bronchodilators.17
Even though the natural time course of TAS in respiratory 
diseases has not been investigated todate, serum TAS increased 
after a week of appropriate treatment in both groups of patients 
following improvement of the clinical and laboratory findings. 
According to clinical experience, most of pneumonia patients 
show improvement in clinical and laboratory findings within 
a week period. Thus, we arbitrarily chose the seventh day to 
estimate TAS changes in order to correlate these changes with 
pneumonia improvement.
Comparison of TAS measurements in both groups of 
patients revealed significantly lower values in pneumonia 
patients as opposed to the asthmatics. A plausible explana-
tion could be the role of neutrophils through the oxidative 
burst phenomenon. It is known that the oxidative response of 
activated phagocytes is a primary host defense mechanism in 
pneumonia and that this response is mainly due to neutrophil 
recruitment and activation.19 Furthermore, the host defense 
against Streptococcus pneumonia which is a major cause of 
pneumonia depends on bacterial killing by neutrophils.20
However, there is evidence that at sites of inflammation, 
multiple inflammatory cells including eosinophils, neutrophils 
and macrophages are capable of generating reactive oxygen 
species which can contribute to development of various dis-
eases.21 Especially in asthma, the numbers of inflammatory 
cells -particularly eosinophils- are increased in the airways and 
release large amounts of harmful reactive oxygen species.22 Fur-
thermore, increased cell numbers of activated eosinophils and 
cells with respiratory burst activity in peribronchial tissue and 
peripheral blood have been detected in unstable asthma.23
It seems that the different nature of inflammation that 
characterizes CAP and asthma is not enough to explain the 
differences in TAS values between these diseases, as both neu-
trophils and eosinophils are major sources of reactive oxygen 
species. It is possible that the subacute and more prolonged 
course of pneumonia leads to greater antioxidant reduction 
through increased oxidative load which is not restored even 
at the recovery period.
A limitation of our study is that oral or parenteral steroids 
were given as treatment in asthmatic patients as opposed to 
pneumonia patients who did not receive steroids and this 
could have had an impact on the increase of TAS. However, 
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lack of administration of oral or parenteral steroids in patients 
with severe asthma exacerbation is beyond medical ethics. 
Furthermore, in the present study no statistically significant 
differences in TAS changes during the seven-day period were 
found between the two groups of patients, supporting the 
aforementioned hypothesis as both groups showed similar 
improvement in antioxidant status but in CAP patients the 
initial values were much lower compared to the asthmatics. In 
addition, pneumonia may be related to lower TAS due to the 
fact that there is a more prominent effect observed in peripheral 
circulation. However, there was no significant difference in 
TAS between patients with positive blood culture and those 
without, although the number of those patients was too small 
(3 cases) to provide reliable statistical results.
Smoking habit appeared not to have any influence on 
the oxidative stress in pneumonia and asthmatic patients on 
admission. On the other hand, smokers with pneumonia or 
asthma had no difference in TAS on discharge. A plausible 
explanation could be that usually smokers quit smoking dur-
ing hospitalization.
Measurement of serum total antioxidant status obviously 
offers an overall estimation of the extracellular antioxidant 
capacity. That means that probably most of the antioxidants 
which take part in the colorimetric method used in the present 
study are extacellularly located, although there is evidence 
that major intracellular antioxidant enzymes (e.g. SOD and 
GSH-Px) are also detectable extacellularly even in smaller 
amounts.24
c O n c l u S i O n
The results of our study strongly suggest the presence of a 
profound antioxidant deficiency, through decreased serum TAS, 
in asthmatic patients with severe exacerbation of their disease 
or in patients with community acquired pneumonia. Although 
asthma and pneumonia are pathophysiologically totally dif-
ferent diseases, they are both characterized by inflammation. 
However, the relationship between the decrease in serum TAS 
and the pathogenesis of acute exacerbations of asthma or the 
course of CAP requires further study, as well as the benefit 
of supplementary administration of antioxidants.
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